<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pharmaceuticals on FinanClub</title>
    <link>https://finan.club/tags/pharmaceuticals/</link>
    <description>Recent content in Pharmaceuticals on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 12 Aug 2023 06:56:32 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pharmaceuticals/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Sat, 12 Aug 2023 06:56:32 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:109
Chances: Stronger-than-expected second-quarter earnings indicate the company&amp;rsquo;s financial strength. Positive results from clinical trials and collaborations in the healthcare sector. Rise in revenue and better full-year sales forecast driven by strong Keytruda cancer-drug sales. Expansion of ongoing Phase 1 dose escalation trial for breast cancer vaccine in collaboration with Cleveland Clinic.</description>
    </item>
    
    <item>
      <title> VTRS</title>
      <link>https://finan.club/us/vtrs/</link>
      <pubDate>Tue, 08 Aug 2023 05:56:47 +0000</pubDate>
      
      <guid>https://finan.club/us/vtrs/</guid>
      <description>score:1188
Chances: Viatris shares advanced after posting better-than-expected Q2 2023 results and announcing planned divestitures, including a new multiple sclerosis treatment in collaboration with Mapi Pharma. Viatris CEO plans $9 billion in divestitures to optimize the company&amp;rsquo;s business lines and products, a third of which is already completed.</description>
    </item>
    
  </channel>
</rss>
